The management of osteoporosis typically focuses on bone-specific interventions, such as bisphosphonates, monoclonal antibodies targeting receptor activator of NFκB ligand (RANKL), selective oestrogen receptor modulators (SERMs), and parathyroid hormone (PTH) analogues [2,11]. The gene discussed is PTH; the disease is osteoporosis.